New cocktail targets brain lymphoma: early trial launches
NCT ID NCT06730542
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adults will take part. The main goal is to check for serious side effects; researchers will also watch whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanubrutinib (a targeted cancer drug taken as capsules) combined with standard chemotherapy drugs (Polatuzumab Vedotin, Rituximab, Cyclophosphamide, and high-dose Methotrexate)
What this could lead to
If this combination is safe and effective, it could offer a new treatment option for patients with lymphoma that has spread to the brain or spinal cord.
What could go wrong
This is a very early (Phase 1) trial with only 20 people, so the main goal is safety, not proof of benefit. The drug combination may cause serious side effects, and it is not yet known if it will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact